Long-term efficacy and safety data through two years of upadacitinib in patients who had an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) and were bDMARD-naïve. Efficacy of upadacitinib on axial symptoms in people with active psoriatic arthritis and axial involvement. Data on sustainability of response to upadacitinib among patients with prior inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs (bDMARDS). Long-term safety and efficacy data through three years of upadacitinib and adalimumab for patients with prior inadequate response to methotrexate (MTX). "The data we're presenting at this year's ACR meeting reflect our commitment to advancing our portfolio of medicines to help more people achieve meaningful disease control."ĭata evaluating the long-term safety and efficacy of RINVOQ, will be presented, including: 
"Many people continue to struggle with the daily, debilitating challenges of rheumatic diseases," said Brandee Pappalardo, Ph.D., M.P.H., vice president, U.S. A total of 38 abstracts, including two oral presentations and one plenary session presentation, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. 1, 2021 /PRNewswire/ - AbbVie (NYSE: ABBV) today announced the presentation of new data on RINVOQ ® (upadacitinib), SKYRIZI ® (risankizumab) and HUMIRA ® (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2021), to be held virtually Nov.
0 kommentar(er)
